Thelansis

Gastric Cancer Emerging Therapy and TPP Insights Thelansis’s “Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Gastric Cancer Overview Gastric cancer is the fifth most common malignancy and third leading cause of cancer mortality globally, arising predominantly as adenocarcinoma from the gastric mucosa, with Helicobacter pylori infection, dietary carcinogens, tobacco, obesity, and hereditary syndromes including CDH1 germline mutations constituting principal aetiological drivers. Molecular classification encompasses EBV-positive, microsatellite instability-high, chromosomally unstable, and genomically stable subtypes, each carrying distinct therapeutic implications. HER2 amplification occurs in approximately ...

Gastric Cancer Emerging Therapy and TPP Insights Thelansis’s “Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and ...

Gastric Cancer Market Outlook Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do in...

Gastric Cancer Market Outlook Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Gastric Cancer Overview Gastric cancer is the fifth most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related death, with higher prevalence in men. Fibroblast growth factors (FGFs) play a pivotal role in its pathogenesis by binding to FGFRs, triggering intracellular tyrosine phosphorylation and downstream signaling cascades. FGFR2 protein is overexpressed in approximately 20–30% of gastric cancers—particularly in diffuse-type and s...

 Gastric cancer ranks the fourth most prevalent malignancy among men and the seventh among women. In the context of this disease, fibroblast growth factors (FGFs) play a critical role by binding to FGFR, subsequently leading to phosphorylation at intracellular tyrosine residues. This, in turn, triggers downstream signaling activation. In roughly 30% of gastric carcinomas, there is an observable overexpression of the FGFR2 protein. This overexpression correlates positively with scirrhous cancer, a diffuse type of cancer, invasion depth, infiltration type, and a less favorable prognosis. Approximately 5-10% of gastric cancer patients exhibit amplification of FGFR2. Several factors are associated with an elevated risk of developing gastric cancer. These factors encompass dietary elements such as high-salt intake from salt-preserved foods, consumption of N-nitroso compounds from dietary sources, smoking, inadequate intake of vitamins A and C, excessive consumption of smoked or cured fo...

 Gastric cancer is the fourth most common malignant disease in men and the fifth in women. Fibroblast growth factors (FGFs) bind to FGFR, which subsequently undergoes phosphorylation at intracellular tyrosine residues, leading to the activation of downstream signalling. FGFR2 protein overexpression was observed in about 30% of gastric carcinomas and was positively correlated with scirrhous cancer, a diffuse type, invasion depth, infiltration type and a poor prognosis. The amplification of FGFR2 has been evident in approximately 5-10% of gastric cancer patients. FGFR2 amplification occurs more frequently in diffuse-type gastric cancer. However, there was no association found of FGFR2 amplification with histological subtype. Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical pr...